This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Should You Buy Merit Medical (MMSI) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
MMSIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Drug, Biotech Stocks' Q4 Earnings Due on Jan 31: NVO, NVS & GSK
by Ahan Chakraborty
Let's look at three biotech/drug companies, NVO, NVS and GSK, slated to release quarterly results on Jan 31.
GSKPositive Net Change NVSPositive Net Change JNJPositive Net Change NVOPositive Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca's (AZN) sBLA for Enhertu Gets FDA's Priority Tag
by Zacks Equity Research
AstraZeneca's (AZN) sBLA for Enhertu to treat metastatic HER2-positive solid tumors gets priority review status by the FDA. A final decision is expected in second-quarter 2024.
AZNPositive Net Change PBYIPositive Net Change DERMPositive Net Change CTMXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Novo Nordisk (NVO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Novo Nordisk's (NVO) sales in fourth-quarter 2023 are expected to have been driven by increased Diabetes and Obesity Care product sales despite pricing pressure in the United States.
SNYPositive Net Change AZNPositive Net Change NVSPositive Net Change NVOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Apellis (APLS) Down on Negative CHMP Opinion for Pegcetacoplan
by Zacks Equity Research
Apellis (APLS) stock falls on the CHMP's negative recommendation to the EMA regarding the approval of intravitreal pegcetacoplan in the EU for the treatment of geographic atrophy secondary to age-related macular degeneration.
PBYIPositive Net Change DERMPositive Net Change CTMXPositive Net Change APLSPositive Net Change
biotechnology biotechs medical pharmaceuticals
5 U.S. Corporate Giants to Buy on Solid Economic Data
by Nalak Das
We have narrowed our search to five U.S. corporate giants that have strong potential for 2024. These are: NFLX, PGR, BK, ANET, REGN.
REGNNegative Net Change BKPositive Net Change NFLXNegative Net Change PGRPositive Net Change ANETPositive Net Change
biotechnology communications consumer-discretionary finance insurance
Incyte (INCY) Banks on Opzelura as Jakafi Faces Competition
by Zacks Equity Research
Incyte (INCY) is likely to rebound in 2024 on the solid growth of Opzelura and additional label expansions.
GSKPositive Net Change NVSPositive Net Change INCYNegative Net Change
biotechnology biotechs pharmaceuticals
What You Need to Know Ahead of Bristol-Myers (BMY) Q4 Earnings
by Zacks Equity Research
Investors are likely to focus on Opdivos demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.
GSKPositive Net Change BMYNegative Net Change NVOPositive Net Change MRKPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion
by Zacks Equity Research
Heron (HRTX) rises 19% on label expansion of its postoperative pain management drug, Zynrelef, to include additional orthopedic and soft tissue procedures.
PBYIPositive Net Change HRTXPositive Net Change DERMPositive Net Change CTMXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Top Research Reports for Novartis, Amgen & Palo Alto Networks
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), Amgen Inc. (AMGN) and Palo Alto Networks, Inc. (PANW).
NVSPositive Net Change ERICPositive Net Change AMGNNegative Net Change BROPositive Net Change PANWPositive Net Change PTCPositive Net Change
biotechnology computers pharmaceuticals
Novartis (NVS) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.
GSKPositive Net Change NVSPositive Net Change NVOPositive Net Change MRKPositive Net Change
biotechnology earnings pharmaceuticals
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
by Zacks Equity Research
Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.
SNYPositive Net Change GILDNegative Net Change EXELNegative Net Change INBXPositive Net Change
biotechnology biotechs pharmaceuticals
Flexsteel Industries (FLXS) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
FLXSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update
by Zacks Equity Research
Unicycive (UNCY) rises after the encouraging progress in the late-stage development of its lead candidate, OLC, for the hyperphosphatemia indication. The NDA submission is expected around mid-2024.
PBYIPositive Net Change ADMAPositive Net Change CTMXPositive Net Change UNCYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study
by Zacks Equity Research
Outlook (OTLK) stock rises after aligning with the FDA regarding the protocols of a non-inferiority study of ONS-5010 for AMD. The study is set to become the basis for BLA resubmission by 2024-end.
REGNNegative Net Change PBYIPositive Net Change ADMAPositive Net Change OTLKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal
by Zacks Equity Research
Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.
REGNNegative Net Change GILDNegative Net Change IMGNPositive Net Change ABBVPositive Net Change
biotechnology biotechs pharmaceuticals
Keros Therapeutics, Inc. (KROS) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
KROSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program
by Zacks Equity Research
Pharvaris (PHVS) rises 6% after the FDA lifts the clinical hold on the investigational candidate, deucrictibant, for the prophylactic treatment of HAE attacks.
PBYIPositive Net Change ADMAPositive Net Change ACADPositive Net Change PHVSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Here's Why You Should Add Xenon (XENE) to Your Portfolio Now
by Zacks Equity Research
Xenon's (XENE) late-stage studies in epilepsy are progressing well. The company is also gearing up to initiate a late-stage study for the MDD indication in 2024.
PBYIPositive Net Change ADMAPositive Net Change ACADPositive Net Change XENEPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels
by Ekta Bagri
The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.
NVSPositive Net Change BMYNegative Net Change JNJPositive Net Change GILDNegative Net Change LEGNPositive Net Change
biotechnology biotechs pharmaceuticals
Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy
by Zacks Equity Research
Verastem's (VSTM) avutometinib/Lumakras combination therapy gets the FDA's Fast Track designation to treat KRAS G12C-mutant metastatic NSCLC patients. The stock gains 8% in response.
AMGNNegative Net Change PBYIPositive Net Change ADMAPositive Net Change VSTMPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
S&P 500 Index Hits All-Time High: 5 Must-Buy Stocks
by Nalak Das
We have narrowed our search to five S&P 500 stocks that have strong growth potential in 2024. These are: NVDA, REGN, ANET, IT, MLM.
REGNNegative Net Change NVDAPositive Net Change ITPositive Net Change MLMPositive Net Change ANETPositive Net Change
biotechnology business-services communications construction semiconductor
Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx
by Zacks Equity Research
Exelixis (EXEL) gets a favorable ruling from the European Patent Office in a lawsuit related to its oral oncology drug, Cabometyx.
TEVANegative Net Change EXELNegative Net Change PBYIPositive Net Change ADMAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study
by Zacks Equity Research
Vor Bio (VOR) stock gains after dosing the first patient in its phase I/II study of novel cell therapy, VCAR33 (Allogenic), to treat AML. The company extends its cash runway into the second half of 2025.
PBYIPositive Net Change ADMAPositive Net Change ACADPositive Net Change VORNo Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Novartis' (NVS) Strong Portfolio, Pipeline to Fuel Growth in 2024
by Zacks Equity Research
Novartis (NVS) is poised to outperform in 2024, backed by a diverse portfolio and a deep pipeline.
REGNNegative Net Change NVSPositive Net Change NVOPositive Net Change CYTKPositive Net Change
biotechnology medical pharmaceuticals